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New results present C-peptide as a biologically active
peptide hormone in its own right. Although C-peptide is
formed from proinsulin and cosecreted with insulin, it is a
separate entity with biochemical and physiological char-
acteristics that differ from those of insulin. There is di-
rect evidence of stereospeciﬁc binding of C-peptide to a
cell surface receptor, which is different from those for in-
sulin and other related hormones. The C-peptide binding
site is most likely a G–protein–coupled receptor. The as-
sociation constant for C-peptide binding is approximately
3 × 109 M−1. Saturation of the binding occurs already at a
concentrationofabout1nM,whichexplainswhyC-peptide
effects are not observed in healthy subjects. Binding of C-
peptideresultsinactivationofCa2+ andMAPK-dependent
pathways and stimulation of Na+,K+-ATPase and eNOS
activities. The latter 2 enzymes are both deﬁcient in sev-
eral tissues in type 1 diabetes. There is some evidence that
C-peptide, and insulin may interact synergistically on the
insulin signaling pathway. Clinical evidence suggests that
replacement of C-peptide, together with regular insulin
therapy, may be beneﬁcial in patients with type 1 diabetes
andservetoretardorpreventthedevelopmentoflong-term
complications.
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INTRODUCTION
Several experimental and clinical studies published in the
past decade have consistently demonstrated that proinsulin
C-peptideisnotasbiologicallyinertaswaspreviouslythought.
Thus, C-peptide binds speciﬁcally to cell membranes and ac-
tivates intracellular signaling pathways, resulting in stimula-
tion of both Na+,K+-ATPase and endothelial nitric oxide syn-
thase (eNOS) activities (Johansson et al., 2002b; Wahren et al.,
2000). Studies in C-peptide deﬁcient type 1 diabetes patients
have shown that replacement of C-peptide is accompanied by
signiﬁcant improvements in renal and nerve function. Thus,
C-peptide replacement partially corrects both the glomerular
hyperﬁltration and the microalbuminuria that characterize the
early stages of diabetic nephropathy (Johansson et al., 1992b,
2000). Likewise, sensory nerve conduction velocity, vibration
thresholds, and autonomic nerve function, which are altered
early on in the course of diabetic neuropathy, improve sig-
niﬁcantly after C-peptide replacement therapy in type 1 di-
abetes patients (Ekberg et al., 2003; Johansson et al., 1996,
2000). Data from animal studies suggest that the ameliora-
tion of nerve dysfunction may be related to a C-peptide–
induced increase in nerve blood ﬂow (Cotter et al., 2003)
and/or to augmented endoneural Na+,K+-ATPase activity (Ido
et al., 1997; Sima et al., 2001). These biochemical and clinical
ﬁndings have prompted the notion that C-peptide deﬁciency
could contribute to the development of long-term complica-
tions in type 1 diabetes, and that C-peptide administration, to-
gether with insulin therapy, may be beneﬁcial in the treatment
and prevention of such complications. In this report, we re-
view the recently presented molecular and cellular effects of
C-peptide.
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C-PEPTIDE STRUCTURE AND MOLECULAR
PROPERTIES
C-peptideoriginatesfromthemidportionofproinsulin,cor-
responding to the segment between the insulin A and B chains.
Itisahighlyacidicpeptide,with5acidicresiduesinthehuman
form and up to 7 in other species, with no counterbalance from
basic residues. The human form is a 31-residue peptide. The
interspecies variability is considerable, with regard to both the
amino acid sequence and the exact number of residues; it is in
the central region of the molecule that the size varies. Some
species, including the mouse, have 2 isoforms that also differ
quite markedly (5 positions between the 2 mouse C-peptide
forms; Figure 1).
The extent of sequence variability in C-peptide resembles
that of relaxin, another hormone from the same protein fam-
ily, but is greater than that of many other bioactive peptides
(Table 1). In mammals, however, 8 residues in C-peptide are
quite well conserved. They correspond to the following posi-
tionsinthehumanC-peptide:1(Glu),3(Glu),6(Gln),11(Glu),
12 (Leu), 26 (Leu), 27 (Glu), and 31 (Gln). From this type of
partial structural conservation, it is obvious that acidic residues
(especially Glu) are important for C-peptide function, not only
overall (the acidic nature of the whole peptide), but also at spe-
ciﬁc positions (conserved, or nearly so). One of these residues,
Glu27, has also been ascribed a particular role in the light of
direct measurements of cellular responses with different ana-
logues (Pramanik et al., 2001; Shafqat et al., 2002; Table 2).
Notably, free Glu also exhibits some C-peptide–like activity
in vitro and can partly displace cell-bound C-peptide (Ohtomo
et al., 1998; Pramanik et al., 2001).
C-peptidedoesnotadoptadeﬁnedconformation,itassumes
a “random coil” structure in solution (Henriksson et al., 2000).
Triﬂuoroethanol may induce an N-terminally positioned heli-
cal structure (Henriksson et al., 2000), but in this solvent, he-
lical formation is frequent also for other peptides. Although
particular structural elements have been suggested to be im-
portant in membrane interactions of C-peptide (Ido et al.,
1997), no direct evidence has been presented for the presence
FIGURE 1
Primary structures of human and mouse C-peptides.
Underlined residue symbols indicate species differences. As
shown, the mouse has 2 C-peptide isoforms, differing in
internal size (gap positions).
TABLE 1
Sequence variability of peptide hormones relating to
pancreatic functions and including all the insulin-family
members
Comparison of human and mouse
forms of bioactive peptides
Number of variable
Hormone Variability (%) versus total residues
Somatostatin 0 0 of 14
VIP 0 0 of 28
Glucagon 0 0 of 29
IGF-1 6 4 of 70
GIP 7 3 of 42
Insulin 8 4 of 51
CCK 9 3 of 33
IGF-2 9 6 of 67
Secretin 15 4 of 27
Pancreatic 17 6 of 36
polypeptide
GRP 19 5 of 27
C-peptide* 35 11 of 31
Relaxin 56 30 of 54
Note. Structures are from data banks (Swiss Prot) and com-
pleted genome sequences (Ensemble).
∗DataforC-peptidearebasedoncomparisonwiththemouse
type 1 C-peptide.
TABLE 2
Correlation of results with C-peptide, the C-terminal
pentapeptide fragment, and its Ala-substituted analogues,
using 2 different methods, ﬂuorescence correlation
spectroscopy (FCS) and increase in intracellular calcium
concentration ([Ca2+]i)
Peptides FCS [Ca2+]i
Full length C-peptide +++ +++
C-terminal pentapeptide EGSLQ +++ +++
EGSLQ analogues
AGSLQ −−
EASLQ +++ +
EGALQ ++ +++
EGSAQ ++
EGSLA ++ ++
Note. The plus signs indicate relative responses in the 2 assay
methods. As shown, the general agreement is excellent, with de-
viations for only some of the analogue forms.
Data from Rigler et al. (1999); Pramanik et al. (2001); Shafqat
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of membrane-induced conformational changes for C-peptide
(Henriksson et al., 2000).
The pronounced interspecies structural variability of
C-peptidehasbeendifﬁculttointerpretinfunctionalterms.Pep-
tides with deﬁned functions are often well conserved (Table 1)
and the absence of strict conservation in C-peptide probably
contributed to the long delay before C-peptide was recognized
as a peptide hormone. The apparent discrepancy between de-
ﬁned functions and a low structural conservation may indicate
either that only limited regions are important for C-peptide
function (thus limiting the extent of necessary conservation),
or that essentially only charge interactions are important (lim-
iting exact sequence conservation as long as at least some Glu
residues are conserved), or that a conserved function exists
onlyinmammals(whereC-peptideconservationisreasonable)
rather than within the whole vertebrate line. Signiﬁcantly, and
in support of these interpretations, the short C-terminal pen-
tapeptidefragmentofC-peptidehasbeenshowntobesufﬁcient
for C-peptide responses in assays (cf below) using Na+,K+-
ATPase (Ohtomo et al., 1998), ﬂuorescence correlation spec-
troscopy(Rigleretal.,1999),andintracellularcalciumconcen-
trations (Shafqat et al., 2002).
In conclusion, the structural and evolutionary properties of
C-peptide show that it lacks a stable conformation in physio-
logical solutions and has a high degree of structural variability.
Moreover, C-peptide has an important C-terminal segment and
elicits measurable molecular and cellular effects that correlate
with functional differences among analogues in a manner com-
patible with hormonal function. In addition, C-peptide is of
structural importance, recognized long ago, in the folding of
the parent proinsulin molecule.
MEMBRANE INTERACTIONS
AND CELLULAR EFFECTS
Binding of C-peptide to Cell Membranes
Speciﬁc binding of C-peptide to cell membranes has
been studied with a new technique, ﬂuorescence correlation
spectroscopy (FCS). In FCS, the Brownian movements of
a ﬂuorophore-marked ligand (tetramethylrhodamine-labeled
C-peptide) are recorded after excitation by a sharply focused
laserbeam.Themeasurementsareperformedinasmallvolume
element (<1×10−15 L) that can be shifted from the incubation
medium above a cell growing in culture to the cell membrane.
The autocorrelation function that describes the spontaneous
ﬂuctuationsinﬂuorescenceintensitywithinthevolumeelement
iscalculated,makingitpossibletodeterminethediffusiontime
of the labeled peptide—when free in the incubation medium or
bound to the cell membrane—and to characterize the nature of
the peptide-cell surface interaction. The FCS technique offers
higherdetectionsensitivityandanimprovedsignal-to-noisera-
tioascomparedtotheconventionalradioligand-bindingmethod
(Eigen and Rigler, 1994; Maiti et al., 1997).
UsingtheFCStechniquewithrhodamine-labeledC-peptide,
C-peptide has been shown to bind speciﬁcally to renal convo-
luted tubular cells, skin ﬁbroblasts, and saphenous vein en-
dothelial cells (Rigler et al., 1999). All cell types were human
and homologous C-peptide was used. The speciﬁcity of the
binding was evidenced by displacement of bound C-peptide
after addition of excess unlabeled C-peptide. Addition to the
incubation medium of scrambled C-peptide (a 31–amino acid
residue peptide with its components arranged in random or-
der) or of the enantio (D-form) C-peptide failed to displace the
bound C-peptide, ﬁndings which attest to the speciﬁcity and
chiral nature of the C-peptide binding to the cell membrane.
Incubation with insulin, proinsulin, insulin-like growth factor
(IGF)-I, IGF-II, or neuropeptide Y (NPY) does not result in
competitive displacement of bound C-peptide, demonstrating
that there is no cross-reactivity between these hormones and
their receptors. Likewise, C-peptide in supraphysiological con-
centrationsdidnotdisplaceboundinsulin.Preincubationofthe
cellswithpertussistoxinabolishedtheC-peptidebindingtocell
membranes (Rigler et al., 1999). The latter ﬁnding is consis-
tent with an allosteric mechanism being involved in C-peptide
signal transduction. Prior to exposure to pertussis toxin, there
wasahigh-afﬁnityinteractionbetweenC-peptideanditsrecep-
tor, reﬂecting one conﬁguration of the receptor; after pertussis
toxin exposure, only a small component of low-afﬁnity interac-
tion remained, suggesting a new conﬁguration of the receptor,
secondary to an effect of pertussis toxin on the α-subunit of the
G-protein (Hamm, 1998).
The binding curve and the Scatchard diagram describing
the interaction between C-peptide and renal tubular cells are
illustrated in Figure 2. The estimated association constant is
approximately 3 × 109 M−1, assuming one receptor binding
site per C-peptide molecule. Similar or slightly lower associa-
tion constants were found for C-peptide binding to ﬁbroblasts
and endothelial cells (Rigler et al., 1999). The C-peptide bind-
ing curve indicates that saturation of binding occurs already
at a concentration of approximately 0.9 nM (Figure 2). This
ﬁnding may be of clinical importance, because no effects of
C-peptide can be demonstrated in healthy individuals or an-
imals (Hoogwerf et al., 1986; Johansson et al., 1992a; Sima
et al., 2001; W´ ojcikowski et al., 1983). It is only in C-peptide–
negativetype1diabetespatientsoranimalsthatseveralphysio-
logical effects of C-peptide have been found (cf. Wahren et al.,
2000). This seeming discordance can now be explained by the
ﬁnding that even a low concentration of C-peptide leads to sat-
uration of C-peptide binding sites. In healthy subjects or ani-
mals,receptorsaturationprobablyoccursalreadyattheambient18 J. WAHREN ET AL.
FIGURE 2
Binding of rhodamine-labeled C-peptide to cell membranes of renal tubular cells. Fractional saturation (y) of the
membrane-bound labeled ligand is presented as a function of the C-peptide concentration (L) in the binding medium. The
binding curve corresponds to Kass = 3.3 × 109 M−1. A corresponding Scatchard plot is shown in the insert. Reproduced from
(Rigler et al., 1999, copyright [1999] National Academy of Sciences, U. S. A.).
C-peptideconcentrationandnofurtherphysiologicaleffectsare
to be expected from an increased concentration.
Species speciﬁcity with regard to C-peptide binding has not
beenstudiedindetailbuthumanC-peptide,albeitatsupraphys-
iological concentrations, is reported to improve nerve function
and lower both glomerular hyperﬁltration and urinary albumin
excretion in the diabetic rat (Huang et al., 2002; Ido et al.,
1997). Likewise, a C-peptide bioassay based on Ca2+ release
(see below) shows cross-reactivity and effects of both the rat
C-peptide and the rat C-terminal pentapeptide in human cells
(Shafqat et al., 2002).
The radioligand method for hormonal binding studies has
also been employed for the evaluation of C-peptide cell
membrane interactions. Tyrosylated 125I-labeled homologous
C-peptide has been reported to bind speciﬁcally to cultured
rat islet cells (Flatt et al., 1986). However, subsequent at-
tempts to document speciﬁc binding of radiolabeled C-peptide
to crude cell membranes from skeletal muscle (Zierath et al.,
1996) and to human renal tubular cells (Rigler et al., 1999)
were not successful. Neither could binding to human lym-
phoblasts be demonstrated (Jehle et al., 1996), but bound la-
beled proinsulin can be displaced by C-peptide (Jehle et al.,
1996, 1999). The variable results and the difﬁculties in demon-
strating cellular binding of C-peptide using radioligand tech-
niques have not been fully explained but the relative paucity of
C-peptide binding sites per unit cell surface area (Flatt et al.,
1986; Rigler et al., 1999) may contribute. The structure of the
C-peptide receptor is not known, but it has been found that
treatment of cells with detergents causes release of solubilized
macromoleculesthatbindspeciﬁcallytoC-peptide(Henriksson
et al., 2001).
Bioactive peptides generally exert their cellular effects via
speciﬁc binding of a limited region of the ligand molecule to
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of human C-peptide (EGSLQ) can competitively displace the
bound,full-lengthpeptide(Rigleretal.,1999),indicatingthein-
volvement of the C-terminal segment as an “active site” in the
binding process. Studies with sequential alanine substitution of
thepentapeptidedemonstratedthatthepentapeptideN-terminal
glutamic acid residue (Glu27) is of particular importance for
the binding process (Pramanik et al., 2001) and for eliciting an
intracellular Ca2+ response (Shafqat et al., 2002; Table 2).
In summary, direct binding studies demonstrate speciﬁc
binding of C-peptide to cell surfaces and to solubilized cell
components. Association constants, binding curves, and dis-
placementcharacteristicshavebeendocumentedatphysiologi-
cally relevant concentrations. The C-terminal pentapeptide has
beenshowntobecapableofcompetitivelydisplacingthebound
full-length peptide, indicating that this segment is involved in
the binding process. A functional receptor has still to be iden-
tiﬁed, but the available data on the binding of C-peptide to cell
membranes provide a molecular basis for its further effects,
discussed below.
Cellular Effects of C-peptide
Intracellular Calcium Concentrations
Several lines of evidence suggest that intracellular Ca2+
functions as a second messenger in the C-peptide signal trans-
duction. Exposure of rat convoluted tubular cells in primary
culture to homologous C-peptide in the physiological concen-
trationrangeisaccompaniedbyapromptelevationoftheintra-
cellular Ca2+ concentration (Ohtomo et al., 1996). The human
full-length C-peptide and its C-terminal pentapeptide are
equally effective in increasing the intracellular Ca2+ in human
renal cells, but scrambled C-peptide has no effect, conﬁrming
the speciﬁcity of the signal (Shafqat et al., 2002). A pentapep-
tide analogue with Glu1 replaced by Ala fails to increase intra-
cellular Ca2+, in agreement with the importance of this residue
for the binding process (Pramanik et al., 2001). Addition of
a calcium chelator to the medium abolishes the effect of C-
peptide, suggesting that the effect is elicited via an inﬂux of
extracellular Ca2+ rather than by release from intracellular de-
pots (Wallerath et al., 2003; Ohtomo et al., 1996). Addition of
pertussis toxin to the medium also prevents the effects of both
C-peptide and the pentapeptide segment on intracellular Ca2+
concentrations, again indicating G-protein involvement in the
C-peptide signaling pathway (Shafqat et al., 2002).
Mitogen-Activated Protein Kinase (MAPK)
C-peptide is reported to induce phosphorylation of the
MAPK extracellular signal-regulated kinases (ERK 1/2) of
a ﬁbroblast cell line (Swiss 3T3), whereas reverse-sequence
C-peptide and an all-D-amino acid C-peptide failed to do so
(Kitamura et al., 2001). Moreover, phosphorylation of ERK
1/2 is also observed in human renal tubular cells upon incuba-
tion with homologous C-peptide and its C-terminal pentapep-
tide segment (Chibalin et al., 2002). Preincubation of the cells
with pertussis toxin or with PD98059, a MAPK kinase 1 in-
hibitor, abolishes the stimulatory effect on ERK phosphory-
lation. C-peptide has also been found to stimulate both p38
stress-activated protein kinase (p38 MAPK) and ERK 1/2 ac-
tivity and phosphorylation in mouse lung capillary endothelial
cells (Kitamura et al., 2002). In addition, C-peptide stimulation
inducesphosphorylationandDNAbindingoftranscriptionfac-
tors and these effects are blocked by a p38 MAPK inhibitor but
notbyanERK1/2inhibitor(Kitamuraetal.,2002).Altogether,
these data constitute evidence that MAPK phosphorylation is
involvedinC-peptidesignaltransductioninaseveralcelltypes.
Na+,K+-ATPase
The level of Na+,K+-ATPase activity is reduced in several
tissues in experimental and human diabetes (De La Tour et al.,
1998; Ido et al., 1997). C-peptide is reported to exert a stim-
ulatory effect on Na+,K+-ATPase activity under both in vitro
and in vivo conditions. Exposure of rat convoluted tubular seg-
ments to homologous C-peptide and its fragments results in
an increase in Na+,K+-ATPase activity as measured by hy-
drolysis of [32P]ATP (Ohtomo et al., 1996, 1998; Tsimaratos
et al., 2002). In rat tubular collecting duct cells, stimulation
of Na+,K+-ATPase activity is reported to be mediated via
protein kinase Cα (Tsimaratos et al., 2003). Similarly, stud-
ies using human tubular cells in primary culture and ouabain-
sensitive uptake of 86Rb+ as a marker of Na+,K+-ATPase
activity have conﬁrmed a concentration-dependent effect of
human C-peptide on Na+,K+-ATPase activity at physiological
concentrations(Chibalinetal.,2002).Thestimulatoryeffectof
C-peptide on Na+,K+-ATPase in human renal cells was abol-
ished both by a protein kinase C inhibitor and by PD 98059,
and the data indicate that regulatory properties and phospho-
rylation sites for the human enzyme differ from those of the
rodent enzyme. Interestingly, C-peptide’s ability to stimulate
Na+,K+-ATPase activity is augmented by more than 2 orders
of magnitude in the presence of subthreshold concentrations
of NPY (Ohtomo et al., 1996). NPY is known to elicit phos-
phorylation of ERK 1/2 (Mullins et al., 2002), suggesting that
the interaction between the 2 peptides may occur at the MAPK
level. Pretreatment of tubular segments or cells with pertussis
toxinorincubationofthecellsinaCa2+-freemediumblocksthe
C-peptide effect (Chibalin et al., 2002; Ohtomo et al., 1996).
Likewise, the stimulatory effect on Na+,K+-ATPase is abol-
ished by pretreatment with FK 506, a speciﬁc inhibitor of the
Ca2+-calmodulin–dependent protein phosphatase 2B (Ohtomo
et al., 1996). The C-terminal pentapeptide segment has been
found to be as potent as the full-length C-peptide in stimulating20 J. WAHREN ET AL.
FIGURE 3
Effects of selected rat C-peptide fragments on Na+,K+-ATPase activity in rat proximal convoluted tubular segments. The
numbers indicate the percent activity of each fragment in relation to that of the intact C-peptide. Data from Ohtomo et al. (1998).
Na+,K+-ATPase activity (Figure 3) (Chibalin et al., 2002;
Ohtomo et al., 1998). In contrast, effects of the truncated
des(27–31) C-peptide or an N-terminal segment are insignif-
icant, whereas some stimulatory effect is observed for mid-
dle segments (Ohtomo et al., 1998) (Figure 3). Replacement
of C-peptide in type 1 diabetic rats for periods of 2 to 8
months results in partial restoration of sciatic nerve Na+,K+-
ATPase activity (Ido et al., 1997; Sima et al., 2001). More-
over, red blood cell Na+,K+-ATPase activity is reduced in
patients with type 1 diabetes (Finotti and Palatini, 1986;
McMillan et al., 1978). The reduction is proportional to
the simultaneous decrease in C-peptide plasma concentra-
tion (Dufayet De La Tour et al., 1998) and can be corrected
by C-peptide administration (Forst et al., 2000). Thus, the
available evidence supports the existence of a direct relation-
ship between C-peptide levels and Na+,K+-ATPase activities
in renal and nerve tissues under both in vitro and in vivo
conditions.
Endothelial Nitric Oxide Synthase Stimulation
The long-term complications accompanying type 1 dia-
betes are primarily attributed to microvascular dysfunction. C-
peptide is reported to stimulate blood ﬂow in several tissues
(Cotter et al., 2003; Ekberg et al., 2001; Hansen et al., 2002;
Johansson et al., 1992a, 1992b, 2004) in patients with type 1
diabetes and in animals with experimental diabetes. The in-
crease in blood ﬂow is accompanied by reduced vascular re-
sistance and increased capillary recruitment (Lindstr¨ om et al.,
1996).Intype1diabetespatients,C-peptidestimulatesforearm
blood ﬂow in a concentration-dependent manner (Ekberg et al.,
2001)andthevasodilatoryeffectofC-peptideonforearmblood
ﬂow is completely abolished when C-peptide is administered
into the brachial artery together with an NOS inhibitor (Cotter
etal.,2003;Johanssonetal.,1999).Likewise,instreptozotocin-
induceddiabeticrats,C-peptidestimulatesnervebloodﬂowand
this effect is completely abolished when C-peptide is coadmin-
istered with an NO blocker (Cotter et al., 2003).
ThereisinvitroevidenceforthenotionthatC-peptideelicits
vasodilatationviareleaseofNO.Usingareportercellassayand
bovineaorticendothelialcells,C-peptidewasfoundtoincrease
the endothelial release of NO in a concentration-dependent and
time-dependent manner (Wallerath et al., 2003). This effect,
measured as cGMP formation in the reporter cells (RFL-6 ﬁ-
broblasts)occurredwithin2minutes.Theeffectwascompletely
abolished in the presence of an NOS inhibitor, and no effect
was found when a calcium binding agent was added to the in-
cubation medium (Wallerath et al., 2003), suggesting that the
vasodilatory effect of C-peptide is Ca2+-dependent and direct.
Although increased expression of eNOS mRNA levels in lung
tissuehasbeenreportedforratsinjectedwithC-peptide(Scalia
et al., 2000), no such effect was apparent in the bovine aortic
endothelialcells(Wallerathetal.,2003).C-peptidemayalsoex-
ert other NO-mediated effects; a cardioprotective effect against
leukocyte-mediated reperfusion injury has been reported in the
isolated rat heart (Young et al., 2000), and C-peptide is a potent
inhibitor of leucocyte-endothelium interactions. This effect is
speciﬁcally related to inhibition of endothelial cell adhesion
molecules via stimulation of NO release from the vascular en-
dothelium (Scalia et al., 2000).
Insulinomimetic Effects of C-peptide
C-peptide at physiological concentrations has been found to
mimicinsulineffectsinL6myoblasts;itactivatesinsulinrecep-
tor tyrosine kinase, insulin receptor substrate (IRS1) phospho-
rylation, phosphoinositol 3-kinase (PI3K) activity, and MAPK
phosphorylation, besides augmenting glycogen synthesis and
increasing amino acid uptake (Grunberger et al., 2001). How-
ever, other studies indicate that C-peptide stimulates glucose
transport in human muscle cells without involving the insulin
receptor or causing tyrosine kinase or PI3K activation (Zierath
et al., 1996). C-peptide at up to supraphysiological concen-
trations fails to stimulate glycogen synthesis in mouse soleus
muscle (Shashkin et al., 1997). In vivo studies in diabetic rats
demonstrated a marked stimulation of whole body glucose
turnover in the short term (Ling et al., 1999). Similarly, a mild
to modest stimulation of glucose turnover was seen in type 1
diabetespatientsinshort-termstudies(Johanssonetal.,1992b),
but little or no effect on blood glucose levels or metabolic con-
trol has been observed in long-term (3 months) studies (Ekberg
et al., 2003; Johansson et al., 2000).
Additional receptor systems, not involving G-proteins, have
also been associated with C-peptide. Interactions betweenC-PEPTIDE MOLECULAR AND CELLULAR EFFECTS 21
C-peptide and receptors with catalytic activity are suggested
by results showing that C-peptide may alter the activity of pro-
tein tyrosine phosphatase (Li et al., 2001), an enzyme that may
inactivate the insulin signaling pathway by dephosphorylation
of the insulin receptor, IRS1, and MAPK. C-peptide interac-
tions with ligand-gated ion channels coupled to glutamate re-
ceptors have also been considered both in view of the capacity
of free glutamic acid to partly displace C-peptide from cell
membranes, and considering the importance of N-terminal Glu
for binding and biological activity of intact C-peptide and its
C-terminal pentapeptide (Bourguignon et al., 1994; Pramanik
et al., 2001).
Nonreceptor Interactions
It has been suggested that the effects of C-peptide may be
mediated by a direct interference with the structure of the cell
membrane instead of by binding to a stereospeciﬁc receptor
(Ido et al., 1997). Human C-peptide in supraphysiological con-
centrations, an all D-amino acid C-peptide and a retrosequence
FIGURE 4
Schematic representation of cellular effects of C-peptide. The available evidence is compatible with the hypothesis that
C-peptide binds to a cell membrane receptor coupled to a pertussis toxin sensitive G-protein. The G-protein signal opens Ca2+
channels, resulting in a rise in the intracellular Ca2+ concentration, with subsequent stimulation of endothelial nitric oxide
synthase (eNOS) activity, formation of NO, and vasodilatation. There is also stimulation of the MAP kinase signaling pathway,
resulting in augmented Na+,K+-ATPase activity. In addition, C-peptide and insulin may interact synergistically on the insulin
signaling pathway.
C-peptide were all found to partially correct diabetes-induced
vasculardysfunctioninaratmodeloftype1diabetes(Idoetal.,
1997). The ﬁndings were taken to indicate that the C-peptide
effect may have been mediated in a manner similar to that for
antibiotic peptides, involving clustering on the cell membrane
and pore or ion channel formation (Bessalle et al., 1990). How-
ever, direct measurements indicate that C-peptide fails to as-
sociate in a stable manner with lipid-containing membranes
or micelles (Henriksson et al., 2000). Moreover, it should be
noted that C-peptide does not possess the characteristics of a
channel-forming peptide; it does not show a tendency to self-
associate,isoverallhydrophilicandpolar(negativelycharged),
and lacks a speciﬁc structure in solution (Henriksson et al.,
2000). It is therefore unlikely that the effects of C-peptide
aremediatedviaconformation-dependent,nonchiralmembrane
interactions.
The currently available information presented above pro-
vides a general outline of the intracellular signal transduc-
tion pattern for C-peptide (Figure 4). This pattern involves22 J. WAHREN ET AL.
interaction of the peptide with a G-protein–coupled membrane
receptor and activation of Ca2+-dependent intracellular signal-
ing pathways. The latter include phosphorylation of protein
kinase C and the MAPK system, eliciting increased activity of
Na+,K+-ATPase.TheincreaseintheintracellularCa2+ concen-
tration also gives rise to increased eNOS activity, NO forma-
tion,andvasodilation.Inaddition,somestudiesindicatethatC-
peptide and insulin may interact synergistically on the insulin
signaling pathway.
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